cyrilzakka/clinical-trials huggingface dataset:
V-sitting Posture Stabilization Versus Modified Clamshell in Patients With Non-specific Chronic Low Back Pain.

The aim of this study is to compare the v-siting posture stabilization and clamshell exercises on pain and disability in patients with non-specific chronic low back pain.

Chronic low back pain (LBP) is a common musculoskeletal pain disorder that affects most adults and has the highest prevalence among other chronic musculoskeletal pain disorders. Non-traumatic lower back pain can have different etiologies: intervertebral disc related, vertebral body related, and facet joint related and sacroiliac joint related. Non-specific low back pain affects people of all ages and is a leading contributor to disease burden worldwide. Non-specific low back pain does not have a known pathoanatomical cause. Treatment of non-specific chronic low back pain includes manual therapy, exercise therapy, massage, acupuncture, yoga, cognitive behavioral therapy, and intensive interdisciplinary treatment.

Previous studies have compared the effects of different exercise therapies, other treatment modalities, osteopathic techniques, manual therapies, and yoga and eurhythmy therapy for the management of low back pain. There is very little literature found to evaluate the effects of single movement technique V-sitting exercises and modified clamshell exercises in the management of non-specific chronic low back pain. Previous literature showed less treatment sessions and follow up periods as they are barrier to see the exact picture of effects of treatment protocol followed. In contrast longer duration of treatment regime allow deep insight of the effects of the main treatment body. This study will fulfill these literature gaps. This study will find the comparative effects of V-sitting posture stabilization and Modified Clamshell exercises in the treatment of non-specific chronic low back pain with more treatment sessions in both genders.

Eligibility Criteria:
Inclusion Criteria:

* Patients with non-specific low back pain for more than 3 months
* Subjects being able to sustain 5 seconds of isometric hip abduction in the side-lying position
* Negative Crossed Straight leg raise test
* Negative Straight leg raise test

Exclusion Criteria:

* Metabolic Bone disease (Osteoporosis)
* Any History of Hip pathology
* History of trauma
* History of systemic disease (Rheumatologic disorders, spondylitis, spinal cord disease)
* Radiculopathy
Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

Metoprolol is frequently administered to cardiac surgery patients to reduce the incidence of postoperative atrial fibrillation (PoAF). Metoprolol is metabolized by the enzyme CYP2D6, which is known to have many mutations that could influence a patient's ability to metabolize the drug. In this prospective clinical trial, the investigators will determine the genotype of CYP2D6 for patients undergoing cardiac surgery, provide an altered dosing recommendation for metoprolol, then report the relative effectiveness in managing PoAF for each pharmacogenetic- guided dosing category. The investigators will also explore the effects of personalized metoprolol dosing recommendations on outcomes in hospital length of stay, cost, and provider participation.


Eligibility Criteria:
Inclusion Criteria:

* Age greater than or equal to 18 years
* Scheduled for surgical procedure (coronary artery bypass graft and/or valve repair/replacement) at Vanderbilt University Medical Center

Exclusion Criteria:

* History of allergic reactions or contraindications to beta-blockers
* Patients with persistent atrial fibrillation
Clinical Related Study on Surgical Treatment of Knee Joint Meniscus Injury

Through the analysis of the data of 8094 patients with knee meniscus injury before December 31, 2008 and more patients with partial meniscus resection, subtotal resection and total resection, we can understand the gender difference and ratio of medial and lateral meniscus injuries. Differences, differences in locations, differences in tearing methods, differences in surgical methods, and the course of the disease affect the meniscus injury and surgical methods, and further affect the patient's knee degeneration imaging, accompanying cartilage injury, knee osteoarthritis, Partial resection, subtotal resection and meniscus regeneration after total resection, imaging and secondary arthroscopic exploration (Second-Look) were studied.

Through the data of 8094 patients with knee meniscus injury who underwent surgery at the Institute of Sports Medicine of the Third Hospital of Beijing Medical University before December 31, 2008, and the patients who underwent meniscus suture, partial resection, subtotal resection, and total resection. Analyze and understand the influence of gender difference, ratio difference, position difference, tearing method difference, surgical method difference and disease course on the meniscus injury situation and operation method of the internal and lateral meniscus injury. Observation and research will also be conducted on reports of knee cartilage injury, knee osteoarthritis, and meniscus regeneration after partial meniscus resection, subtotal resection and total resection.

Eligibility Criteria:
Inclusion Criteria:

Before December 31, 2008, patients who underwent surgery for meniscus injury in this institute and patients who underwent meniscus suture, partial resection, subtotal resection, and total resection.

Exclusion Criteria:

-
Efficacy of Neuromuscular Training in Youth Soccer Players

Soccer stands as one of the most widespread sports that ensures active participation . It has continued to grow and develop since its inception in all societies

Footballers suffer injuries in various ways during training sessions and matches throughout the season due to excessive strain. Hence, numerous studies have investigated the injury sites and frequencies of footballers. According to these findings, it has been determined that young footballers experience more lower extremity injuries compared to professional footballers.

Eligibility Criteria:
Inclusion criteria:

* Being between the ages of 15-16
* Playing amateur football for at least 2 years
* Being a male athlete
* Voluntarily participate in the study
* Obtaining informed consent from them

Exclusion criteria:

* Bone fractures, fractures, ligament and muscle tears in the body.
* Has a systemic disease
* Having a serious injury in the last 3 months.
* Having any neurological problem
Effect of Biomagnetic Therapy on Gonarthrosis

In order to assess the effectiveness of biomagnetic therapy (PST) in the treatment of gonarthrosis, we conducted a randomized, double blind controlled clinical trial comparing one group of patients treated with PST and a second group of patients treated with conventional physical therapy.


Eligibility Criteria:
Inclusion Criteria:

* at least 35 years old
* local symptoms over a period of at least one-year
* persistent symptoms despite non steroidal anti-inflammatory drugs
* informed consent

Exclusion Criteria:

* operative treatment in the last six months
* intra-articular injection in the last four months
* rheumatic disease
* homolateral coxarthrosis
* malignant disorder
* body mass index greater than 33%
* pregnancy
* inability to understand the visual analog scale
Manual vs Amigo SmartTouch Atrial Fibrillation Study

Atrial fibrillation is a common form of heart rhythm disturbance that for some patients is treated by catheter ablation (making an ablation lesion or burn inside the heart using a fine wire (catheter)). A new system for manipulating the catheters has recently been introduced into clinical practice (the Amigo Remote Catheter System (RCS)). This trial is designed to answer two primary questions: a) is the contact force (the force with which the catheter comes into contact with the heart) any different using the RCS to manual techniques,and b)are the resulting ablation lesions within the heart any different in terms of the volume and contiguity of the lesions produced. Additionally the investigators aim to determine how the two techniques compare in success (the proportion of patients whose heart rhythm disturbance is corrected by the procedure).

The trial aims to recruit 50 patients, randomised into two groups, to have ablation for atrial fibrillation performed either using the RCS, or manually. Contact force information will be collected during the procedure, but the operators will be blinded to this information. Patients will have follow-up to include post-procedural cardiac magnetic resonance imaging and ambulatory electrocardiograms.

Eligibility Criteria:
Inclusion Criteria:

* atrial fibrillation
* scheduled for catheter ablation

Exclusion Criteria:

* contraindication to magnetic resonance imaging
* pregnancy
* life expectancy of less than six months
* participation in another trial that would conflict with this trial
Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green

The purpose of this study is to determine the correct volume of lissamine green to use when assessing conjunctival staining, and to determine the time course needed to evaluate conjunctival staining after lissamine green has been instilled in the eye.


Eligibility Criteria:
Inclusion Criteria:

* conjunctival staining

Exclusion Criteria:

* ocular pathology
Effect of Stellate Ganglion Block on ME/CFS

The goal of this clinical trial is to study the effects of stellate ganglion block (SGB) in participants with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The main questions it aims to answer are:

Does SGB treatment improve symptoms of ME/CFS (e.g. brain fog, fatigue)? Do changes in symptoms go along with changes in blood or saliva?

Participants will receive a total of six blocks over three weeks (one block on each side, one day apart, per week). Prior to treatment and at two points following treatment, participants will complete surveys, take a cognitive (puzzle type) test, and provide blood and saliva for analysis. Participants will measure their heart rate daily using a free smart phone app.


Eligibility Criteria:
Inclusion Criteria:

* Age (18-50 years)
* Female
* ME/CFS (CCC and IOM criteria) duration less than 4 years at time of study enrollment
* Confirmed or suspected viral disease prior to ME/CFS onset (e.g., SARS-CoV-2, Epstein-Barr, Influenza)
* BMI =18-29 kg/m\^2
* Ability to read, write and speak English language

Exclusion Criteria:

* Prior SGB treatment
* Allergy to amide local anesthetics (e.g. ropivacaine, bupivacaine)
* Current anticoagulant use
* History of bleeding disorder
* History of glaucoma
* Infection or mass at injection site
* Anatomical abnormalities in C3-T1 region
* Current pregnancy
* Hypertension
* Diabetes (any type)
* Thyroid disease
* History of neck or throat surgeries
* Vocal cord problems or paralysis
* Causalgia/Chronic Regional Pain Syndrome (CRPS)
* Current cancer diagnosis
* Diagnosis of Guillain-Barré syndrome
* Diagnosis of current moderate or severe substance use disorder
* History of neurological disease, seizure, or significant head trauma
* Conditions or disorders (other than ME/CFS) that affect cognitive functioning including stroke, past or present diagnosis of psychosis or psychotic symptoms, diagnosis of bipolar I disorder, or severe depression
Multimodal EEG and NIRS-based BCI With Assistive Soft Robotics for Stroke (MBCI-SR)

One-third of patients who had stroke suffered persistent disabilities, and upper limb (UL) motor impairment is one of the main disabilities. Recent clinical studies had been conducted using non-invasive EEG-based BCI via motor imagery, for post-stroke rehabilitation, yielded motor improvement of 7.2 on the Fugl-Meyer Motor Assessment (FMA-UE)score in chronic stroke patients that is significantly better than standard care. However, all the stroke patients underwent the same "one-size-fits-all" treatment option involving all six different activities of daily living (ADL)-oriented tasks regardless of their impairment or ability.

Investigators hypothesize that precision personalized stroke rehabilitation intervention that is tailored to the patient hold more promise than a "one-size-fits-all" stroke rehabilitation strategy.

1. To address the "one-size-fits-all" stroke rehabilitation strategy, RRIS will develop an Ability data-driven personalized stroke rehabilitation based on the stroke patient's UL impairment and motor ability, by first matching 6 UL tasks in RRIS Ability Database with the 6 ADL tasks of the BCI-SR Intervention via similarity indices. A personalized subset of ADL tasks treatment options is then generated by a data-driven recommendation based on the patient's ability, movement pattern of the treatment option and the normative data from the RRIS Ability Database. A multi-modal BCI is proposed to perform EEG subject-specific calibration using Near-infrared spectroscopy, NIRS to ensure motor imagery compliance.
2. stroke subjects with UL impairments (score 11-45 on the FMA-UE) will be recruited to undergo the UL tasks assessment at RRIS. They will then undergo the personalized stroke rehabilitation using the Multimodal EEG and NIRS-based BCI with Soft Robotic therapy for 1.5 hour over 6 weeks, 3 times a week. The effectiveness of the personalized stroke rehabilitation can then be retrospectively compared to the use of "one-size-fits-all" ADL tasks in the previous clinical trial.

Eligibility Criteria:
Inclusion Criteria:

* first ever stroke prior to clinical trial
* Fugl-Meyer Assessment scale of upper extremity impairment of 11-45 out of a maximum score of 66
* ability to give own consent
* ability to pay attention and maintain supported sitting for 1.5 hours continuously
* able to comprehend and follow commands
* fulfils BCI resting brain states on initial screening
* unilateral upper limb impairment

Exclusion Criteria:

* recurrent stroke
* inability to follow command and sit upright for 1.5 hours
* hemi-spatial neglect
* spasticity assessed by Modified Ashworth Scale more than 2/4
* History of Epilepsy
* Fixed contracture / deformity of finger joints
* upper limb pain impeding movements with visual analogy scale \> 4/10
* Severe aphasia or cognitive impairment despite visual aids
* other conditions ensuing upper limb weakness
* poor skin conditions
* skull defect that might affect EEG or NIRS reading
* allergy to electrodes or adhesive gel
* significant vision and hearing impairment affecting participation
* Pregnant women
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum -resistant ovarian cancer.


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically confirmed ovarian adenocarcinoma
* Patients had to have received a front-line, platinum- based chemotherapy regimen
* Patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer. This category also will include patients with disease progression within six months of completing the most recent platinum-based chemotherapy
* Patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area, or increased Ca 125
* A \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment
* Age \> 18 years old
* Performance status (WHO) 0-2
* Life expectancy of at least three months
* Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)
* Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl)
* Informed consent

Exclusion Criteria:

* Pregnant or nursing
* Psychiatric illness or social situation that would preclude study compliance
* Other concurrent uncontrolled illness
* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer
A Feasibility Study to Evaluate Self-Harm Group in Inpatient Settings

The current research is being undertaken as part of a professional doctorate in clinical psychology, which aims to evaluate the feasibility of a group programme to address self-harm within 23 days, to provide evidence for a controlled trial. The intervention will include four group sessions conducted over 2 weeks, based on Dialectical Behavioural Therapy. Specifically the aims are to determine 1) means and a standard deviation for two pre and post treatment outcome measures in order to estimate sample size for the main study, 2) the need for an inpatient intervention for self-harm measured by number of participants eligible and accepting of the treatment, 3) retention of participants for 4 groups given the predicted short stays of patients on wards, and 4) the acceptability of the research process for this client group through feedback.


Eligibility Criteria:
Inclusion Criteria:

* Participants will be screened by their allocated clinician and included if they are aged between 18-65
* admitted to hospital
* have a history of or engaged in at least one episode of self-harm, iv) have capacity to understand the information sheet.

Exclusion Criteria:

* Participants will be screened by clinicians and they will exclude people if i) they are Non-English speakers (due to translation costs)
* they lack the capacity to give informed consent (assessed by their key clinician)
* their symptoms prevent them from concentrating for an hour at a time (i.e. severe thought disorder), and therefore not benefiting from the group (assessed by their key clinician)
Intraligmentary Dexamethasone in Lower First Molars With Irreversible Pulpitis and Apical Periodontits

Using intraligmentary dexamethasone to reduce the pain intensity during and after root canal preparation

Aim :asseing the effect of intraligmentary dexamethasone on anesthetic efficacy of inferior alveolar nerve block and buccal infiltratation in lower first molar with irreversible pulpitis and apical periodontits, dexamethasone has antiinflammatory effect so it will improve the efficacy of anathesia and reduce postoperative by inhibition the production of phosopholipase and reduction of prostaglandins synthesis

Methods: diagnose the case clinically and readiographically Patients will divide into 3 groups First group will be given inferior alveolar nerve block 4%articaine Hcl1:100 epinephrine Second group will be given inferior alveolar nerve block 4%articaine with intraligmentary dexamethasone Third group will be given buccal infiltratation 4%articaine with intraligmentary dexamethasone After anathesia ,make access cavity and reduce the occulsa surface and make it out of occulsion .

Working length determination will be done by apex locator and confirm it by x ray .

Mechanical preparation will be done by FANTA files and apply EDTA on files Irrigate the canal by Naocl 2.5٪ Complete the root canal preparation through single visit. Obturate the canal by single cone technique and bioceramic sealer. During procedures , record pain intensity on HP visual scale Follow up the patient after 6,12,24 and 48 hours Describe Ibuprofen 200mg in case of sever pain Conclusion : it's predictable that the intraligmentary dexamethasone will reduce the pain during and after root canal procedures

Eligibility Criteria:
Inclusion Criteria:

1. Age between 20-45 years old.
2. Systemically healthy patient (ASA I or II).
3. Lower first molar with:

   * Preoperative sharp pain.
   * Slight widening in the periodontal ligament (PDL).
   * Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).

Exclusion Criteria:

1. Patients allergic to anesthetics, or dexamethasone (other corticosteroids).
2. Pregnant or nursing females.
3. Patients having significant systemic disorder (ASA III or IV).
4. Hemostatic disorders or anti-coagulant therapy during the last month.
5. Consumption of opioid or non-opioid analgesics or corticosteroids during the last 12 h before treatment.
6. Retreatment cases.
Evaluation of Type 2 Diabetes Treatment

The aim of this study is to analyze the efficacy of Diabeton 60 MR as intensive sugar-lowering therapy into routine clinical practice, in patients for whom the treating physician has already decided to prescribe this medication. This concerns untreated newly diagnosed patients uncontrolled by diet, and patients uncontrolled by metformin.


Eligibility Criteria:
Inclusion Criteria:

- Type 2 diabetes patients:

* Males and females, aged over 35
* Currently treated: with diet only, or with metformin therapy for at least 3 months prior to inclusion
* Who have not been able to achieve target level of glycaemia, with glycated hemoglobin (HbA1c) level exceeding 7%.

Exclusion Criteria:

Patients with at least one of the following criteria are not included in the study:

* Type 1 diabetes
* Severe liver (ALT and AST levels 2.5 times as high as upper level of normal range) or renal insufficiency (creatinin plasma level above 140 µmole/L)
* Patients who are on insulin therapy, or at risk to receive an insulin treatment in the next 4 months, according to physician judgment.
* Intolerance to Gliclazide if such prescription was done in the past
* Pregnancy and breast-feeding
* Night workers or patients able to skip meals
* Presence of any contraindication listed in the SmPC.